Press Releases

Press Releases

April 3, 2018
BeiGene Appoints J. Samuel Su to its Board of Directors BEIJING, China and CAMBRIDGE, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology
April 3, 2018
BEIJING, China and CAMBRIDGE, Mass. , April 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the
March 5, 2018
BeiGene to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. and BEIJING, China, March 05, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs
February 28, 2018
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results CAMBRIDGE, Mass. and BEIJING, China, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and